What is Tolremo?
Tolremo Therapeutics is a biopharmaceutical company dedicated to combating non-genetic cancer drug resistance. The company's core strategy involves targeting transcriptional escape pathways that often lead to treatment failure. Their lead clinical compound, TT125-802, is an orally available small molecule inhibitor designed to disrupt transcriptional addiction in both solid tumors and hematological malignancies. By developing TT125-802, Tolremo aims to enhance the efficacy of existing targeted therapies, thereby improving patient outcomes and tackling a major hurdle in oncology.
How much funding has Tolremo raised?
Tolremo has raised a total of $39M across 1 funding round:
Series A
$39M
Series A (2023): $39M with participation from BioMedPartners
Key Investors in Tolremo
BioMedPartners
BioMed Partners is a venture capital firm specializing in early-stage biotech companies across Europe, with a focus on innovative assets, technology platforms, and strong management teams.
What's next for Tolremo?
With this latest round of major enterprise-level funding, Tolremo Therapeutics is poised to accelerate its development pipeline and clinical trials. The strategic investment signals strong confidence from backers in the company's innovative approach to overcoming drug resistance. Future endeavors will likely focus on advancing TT125-802 through further clinical stages, potentially forging new partnerships, and expanding its therapeutic applications across a broader spectrum of cancers. This capital will be instrumental in scaling operations and solidifying its position in the competitive biopharmaceutical landscape.
See full Tolremo company page
